BofA lowered the firm’s price target on Amdocs (DOX) to $97 from $100 and keeps a Buy rating on the shares. Growth remains constrained and the FY26 guidance for revenue growth and EPS, at 3.7% and $7.44, were below the Street’s forecasts of 4.1% and $7.66, respectively, notes the analyst, who expects the year to start slow and ramp in the second half.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOX:
- Amdocs: Buy Rating Affirmed Amid Strong Backlog, Cloud Growth, and AI Opportunities
- Amdocs Reports Fiscal 2025 Earnings and Strategic Outlook
- Amdocs expands managed services agreement with Globe
- Amdocs signs pact with Vivo to modernize operations support systems
- Amdocs enters multi-year strategic agreement with Telia Finland